Enveric Biosciences is a publicly-traded biotechnology company predominantly focused on leveraging cannabinoids as treatments for cancer and oncology treatment-caused indications. They have recently expanded into the psychedelic space through the acquisition of MagicMed in September 2021.
Enveric has expanded its drug pipeline to include an extensive library (Psybrary™) of patented novel psychedelic molecules. The company recently announced that it has identified several promising novel candidates from its Psybrary™.
Enveric intends to develop novel psychedelic compounds into therapies for indications such as cancer-related stress and post-traumatic stress disorder (PTSD).
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates